COMMUNIQUÉS West-GlobeNewswire

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
02/09/2019
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1]; EVALUATE-HF results [...]
135,000 Orion Corporation A shares converted into B shares
02/09/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 2 SEPTEMBER 2019 at 9.30 EEST 135,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 135,000 [...]
Motif Bio and Hercules Capital Amend Loan and Security Agreement
02/09/2019
NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that its [...]
Herantis Pharma publishes newsletter for July-August
02/09/2019
Herantis Pharma publishes newsletter for July-August Herantis Pharma Plc Press release 2 September 2019 at 9:00 am Herantis Pharma plc (“Herantis”) has published its newsletter for July-August 2019. The newsletter is [...]
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
02/09/2019
Further preclinical and clinical data presentations of its other diabetic eye disease clinical candidates, THR-687 (Pan-RGD Integrin Inhibitor) and THR-317 (anti-PlGF), will also be delivered Leuven, Belgium, 2 [...]
Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
02/09/2019
BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and [...]
Roche presents positive phase III study results for one-dose Xofluza in children with flu
02/09/2019
Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a [...]
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
01/09/2019
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.059)[1] Totality of [...]
Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019
31/08/2019
Phase 2 dose-finding study demonstrated the blood pressure lowering effect of aprocitentan A global Phase 3 study “PRECISION” in patients whose blood pressure remains uncontrolled despite receiving at least three [...]
MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
31/08/2019
Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained, [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/08/2019
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019, that were previously [...]
Dentsply Sirona to Present at the 2019 Baird Global Healthcare Conference on September 4th
30/08/2019
CHARLOTTE, N.C., Aug. 30, 2019 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that it will participate in the 2019 Baird Global Healthcare [...]
Eyecarrot to Participate in NORA 2019 Annual General Conference
30/08/2019
TORONTO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Eyecarrot Innovations Corp. (EYC: TSX-V ) is thrilled to promote its participation in the Neuro-Optometric Rehabilitation Association (NORA) 2019 Annual General Conference, as [...]
Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American
30/08/2019
CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/08/2019
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
30/08/2019
CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30/08/2019
BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Transparency notification
30/08/2019
Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments B.V . Pursuant to Belgian transparency [...]
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
30/08/2019
WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, [...]

Pages